Skip to content

Cellectar Biosciences, Inc.: 10-K/A filed 2024-10-29

What Cellectar Biosciences, Inc. reported in its annual report amendment filed 2024-10-29 (fiscal FY 2023): 38 published measures, 274 facts as tagged in accession 0001410578-24-001704.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2024-10-29
Fiscal period
fiscal FY 2023
Accession
0001410578-24-001704 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Cellectar Biosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-12-3112,075,580USD
At 2023-09-3021,550,765USD
At 2023-06-306,509,165USD
At 2023-03-3114,838,456USD
At 2022-12-3121,589,790USD
At 2022-09-3019,319,513USD
At 2022-06-3025,892,396USD
At 2022-03-3131,990,186USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-12-3125,852,525USD
At 2023-09-3030,349,004USD
At 2023-06-3013,515,042USD
At 2023-03-3112,085,450USD
At 2022-12-3112,054,523USD
At 2022-09-307,169,004USD
At 2022-06-306,598,324USD
At 2022-03-317,481,024USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-12-31-15,158,968USD
At 2023-09-30-28,000,262USD
At 2023-06-30-8,387,900USD
At 2023-03-311,370,983USD
At 2022-12-318,153,244USD
At 2022-09-3010,768,486USD
At 2022-06-3017,912,049USD
At 2022-03-3123,127,139USD
At 2021-12-3129,063,131USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-12-319,564,988USD
At 2023-09-3018,986,443USD
At 2023-06-305,152,972USD
At 2023-03-3112,682,691USD
At 2022-12-3119,866,358USD
At 2022-09-3017,785,322USD
At 2022-06-3024,805,565USD
At 2022-03-3130,634,122USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-42,770,610USD365
2023-07-01 to 2023-09-30-17,520,378USD92
2023-01-01 to 2023-09-30-34,889,488USD273
2023-04-01 to 2023-06-30-10,178,640USD91
2023-01-01 to 2023-06-30-17,369,110USD181
2023-01-01 to 2023-03-31-7,190,470USD90
2022-01-01 to 2022-12-31-31,792,618USD365
2022-07-01 to 2022-09-30-7,511,322USD92
2022-01-01 to 2022-09-30-19,386,162USD273
2022-04-01 to 2022-06-30-5,635,043USD91
2022-01-01 to 2022-06-30-11,874,840USD181
2022-01-01 to 2022-03-31-6,239,797USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-32,376,974USD365
2023-01-01 to 2023-09-30-22,781,274USD273
2023-01-01 to 2023-06-30-14,713,389USD181
2023-01-01 to 2023-03-31-7,183,670USD90
2022-01-01 to 2022-12-31-25,222,301USD365
2022-01-01 to 2022-09-30-17,810,538USD273
2022-01-01 to 2022-06-30-10,797,361USD181
2022-01-01 to 2022-03-31-5,039,783USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-12-31864,038USD365
2023-01-01 to 2023-09-30597,282USD273
2022-01-01 to 2022-12-31225,971USD365
2022-01-01 to 2022-09-30108,115USD273
2022-01-01 to 2022-06-30101,049USD181
2022-01-01 to 2022-03-3130,070USD90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-12-3122,939,642USD365
2023-01-01 to 2023-09-3022,498,641USD273
2023-01-01 to 2023-06-303USD181
2023-01-01 to 2023-03-313USD90
2022-01-01 to 2022-12-319,610,655USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-864,038USD365
2023-01-01 to 2023-09-30-597,282USD273
2022-01-01 to 2022-12-31-225,971USD365
2022-01-01 to 2022-09-30-108,115USD273
2022-01-01 to 2022-06-30-101,049USD181
2022-01-01 to 2022-03-31-30,070USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-12-31-202,761,017USD
At 2023-09-30-194,879,895USD
At 2023-06-30-177,359,517USD
At 2023-03-31-167,180,877USD
At 2022-12-31-159,990,407USD
At 2022-09-30-147,583,951USD
At 2022-06-30-140,072,629USD
At 2022-03-31-134,437,586USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-01-01 to 2023-12-3112,221,571shares365
2023-07-01 to 2023-09-3011,308,738shares92
2023-01-01 to 2023-09-3011,277,231shares273
2023-04-01 to 2023-06-3011,261,217shares91
2023-01-01 to 2023-06-3011,261,217shares181
2023-01-01 to 2023-03-3111,261,217shares90
2022-01-01 to 2022-12-317,055,665shares365
2022-07-01 to 2022-09-306,110,119shares92
2022-01-01 to 2022-09-306,110,123shares273
2022-04-01 to 2022-06-306,110,124shares91
2022-01-01 to 2022-06-306,110,125shares181
2022-01-01 to 2022-03-316,110,126shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-01-01 to 2023-12-3112,221,571shares365
2023-07-01 to 2023-09-3011,308,738shares92
2023-01-01 to 2023-09-3011,277,231shares273
2023-04-01 to 2023-06-3011,261,217shares91
2023-01-01 to 2023-06-3011,261,217shares181
2023-01-01 to 2023-03-3111,261,217shares90
2022-01-01 to 2022-12-317,055,665shares365
2022-07-01 to 2022-09-306,110,119shares92
2022-01-01 to 2022-09-306,110,123shares273
2022-04-01 to 2022-06-306,110,124shares91
2022-01-01 to 2022-06-306,110,125shares181
2022-01-01 to 2022-03-316,110,126shares90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-3.5USD/shares365
2023-07-01 to 2023-09-30-1.55USD/shares92
2023-01-01 to 2023-09-30-3.09USD/shares273
2023-04-01 to 2023-06-30-0.9USD/shares91
2023-01-01 to 2023-06-30-1.54USD/shares181
2023-01-01 to 2023-03-31-0.64USD/shares90
2022-01-01 to 2022-12-31-4.51USD/shares365
2022-07-01 to 2022-09-30-1.23USD/shares92
2022-01-01 to 2022-09-30-3.17USD/shares273
2022-04-01 to 2022-06-30-0.92USD/shares91
2022-01-01 to 2022-06-30-1.94USD/shares181
2022-01-01 to 2022-03-31-1.02USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-3.5USD/shares365
2023-07-01 to 2023-09-30-1.55USD/shares92
2023-01-01 to 2023-09-30-3.09USD/shares273
2023-04-01 to 2023-06-30-0.9USD/shares91
2023-01-01 to 2023-06-30-1.54USD/shares181
2023-01-01 to 2023-03-31-0.64USD/shares90
2022-01-01 to 2022-12-31-4.51USD/shares365
2022-07-01 to 2022-09-30-1.23USD/shares92
2022-01-01 to 2022-09-30-3.17USD/shares273
2022-04-01 to 2022-06-30-0.92USD/shares91
2022-01-01 to 2022-06-30-1.94USD/shares181
2022-01-01 to 2022-03-31-1.02USD/shares90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-60,000USD365
2022-01-01 to 2022-12-31-60,000USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-12-311,090,304USD
At 2023-09-30893,509USD
At 2023-06-30337,434USD
At 2023-03-31376,084USD
At 2022-12-31418,641USD
At 2022-09-30338,944USD
At 2022-06-30364,838USD
At 2022-03-31331,144USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-01-01 to 2023-12-312,410,288USD365
2023-01-01 to 2023-09-301,325,841USD273
2023-01-01 to 2023-06-30827,963USD181
2023-01-01 to 2023-03-31408,206USD90
2022-01-01 to 2022-12-311,452,964USD365
2022-01-01 to 2022-09-301,091,517USD273
2022-01-01 to 2022-06-30723,758USD181
2022-01-01 to 2022-03-31303,805USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-38,960,643USD365
2023-07-01 to 2023-09-30-9,413,460USD92
2023-01-01 to 2023-09-30-26,412,764USD273
2023-04-01 to 2023-06-30-8,294,002USD91
2023-01-01 to 2023-06-30-16,999,303USD181
2023-01-01 to 2023-03-31-8,705,301USD90
2022-01-01 to 2022-12-31-28,813,773USD365
2022-07-01 to 2022-09-30-7,815,486USD92
2022-01-01 to 2022-09-30-21,391,237USD273
2022-04-01 to 2022-06-30-7,435,524USD91
2022-01-01 to 2022-06-30-13,575,751USD181
2022-01-01 to 2022-03-31-6,140,227USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-12-3110,453,213USD
At 2023-09-3020,109,910USD
At 2023-06-305,609,651USD
At 2023-03-3113,846,436USD
At 2022-12-3120,529,601USD
At 2022-09-3018,761,258USD
At 2022-06-3025,285,233USD
At 2022-03-3131,394,542USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-12-3125,358,522USD
At 2023-09-3029,836,254USD
At 2023-06-3012,984,186USD
At 2023-03-3111,537,106USD
At 2022-12-3111,501,542USD
At 2022-09-307,115,235USD
At 2022-06-306,506,110USD
At 2022-03-317,351,310USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-12-315,620,000USD
At 2022-12-312,558,000USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-01-01 to 2023-12-3127,266,276USD365
2023-07-01 to 2023-09-307,034,656USD92
2023-04-01 to 2023-06-306,135,010USD91
2023-01-01 to 2023-06-3012,494,266USD181
2023-01-01 to 2023-03-316,359,256USD90
2022-01-01 to 2022-12-3118,265,711USD365
2022-07-01 to 2022-09-305,210,825USD92
2022-04-01 to 2022-06-304,144,918USD91
2022-01-01 to 2022-03-313,703,831USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-12-3120,744,110shares
At 2023-09-309,918,384shares
At 2023-06-309,740,507shares
At 2023-03-319,740,507shares
At 2022-12-319,385,272shares
At 2022-09-306,110,118shares
At 2022-06-306,110,122shares
At 2022-03-316,110,124shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-12-319,564,988USD
At 2023-09-3018,986,443USD
At 2023-06-305,152,972USD
At 2023-03-3112,682,691USD
At 2022-12-3119,866,358USD
At 2022-09-3017,785,322USD
At 2022-06-3024,805,565USD
At 2022-03-3130,634,122USD
At 2021-12-3135,703,975USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-12-31182,924,210USD
At 2023-09-30166,879,534USD
At 2023-06-30168,971,520USD
At 2023-03-31168,551,763USD
At 2022-12-31168,143,557USD
At 2022-09-30158,352,376USD
At 2022-06-30157,984,617USD
At 2022-03-31157,564,664USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-12-31502,283USD
At 2023-09-30517,566USD
At 2023-06-30532,300USD
At 2023-03-31546,505USD
At 2022-12-31560,334USD
At 2022-09-30138,097USD
At 2022-06-30161,111USD
At 2022-03-31183,286USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2023-12-31553,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2023-12-311,975,213USD
At 2022-12-311,111,175USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2023-12-31884,909USD
At 2022-12-31692,534USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2023-12-3129,780USD
At 2023-09-3029,780USD
At 2023-06-3029,780USD
At 2023-03-3169,431USD
At 2022-12-3181,214USD
At 2022-09-3081,214USD
At 2022-06-3081,214USD
At 2022-03-3181,214USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2023-12-31888,225USD
At 2023-09-301,123,467USD
At 2023-06-30456,679USD
At 2023-03-311,163,745USD
At 2022-12-31663,243USD
At 2022-09-30975,936USD
At 2022-06-30479,668USD
At 2022-03-31760,420USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2023-12-3187,921,644USD
At 2022-12-3172,923,365USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-42,830,610USD365
2022-01-01 to 2022-12-31-31,852,618USD365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-01-01 to 2023-12-3111,694,367USD365
2023-07-01 to 2023-09-302,378,804USD92
2023-04-01 to 2023-06-302,158,992USD91
2023-01-01 to 2023-06-304,505,037USD181
2023-01-01 to 2023-03-312,346,045USD90
2022-01-01 to 2022-12-3110,548,062USD365
2022-07-01 to 2022-09-302,604,661USD92
2022-04-01 to 2022-06-303,290,606USD91
2022-01-01 to 2022-03-312,436,396USD90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2023-01-01 to 2023-12-31192,375USD365
2023-01-01 to 2023-09-30122,415USD273
2023-01-01 to 2023-06-3081,207USD181
2023-01-01 to 2023-03-3142,557USD90
2022-01-01 to 2022-12-31148,435USD365
2022-01-01 to 2022-09-30110,276USD273
2022-01-01 to 2022-06-3077,316USD181
2022-01-01 to 2022-03-3143,417USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-3,869,967USD365
2023-07-01 to 2023-09-30-8,106,918USD92
2023-01-01 to 2023-09-30-8,476,724USD273
2023-04-01 to 2023-06-30-1,884,638USD91
2023-01-01 to 2023-06-30-369,807USD181
2023-01-01 to 2023-03-311,514,831USD90
2022-01-01 to 2022-12-31-3,038,845USD365
2022-07-01 to 2022-09-30304,164USD92
2022-01-01 to 2022-09-302,005,075USD273
2022-04-01 to 2022-06-301,800,481USD91
2022-01-01 to 2022-06-301,700,911USD181
2022-01-01 to 2022-03-31-99,570USD90

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-60,000USD365
2022-01-01 to 2022-12-31-60,000USD365

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2023-01-01 to 2023-12-31-14,998,279USD365
2022-01-01 to 2022-12-31-10,433,496USD365

Inspect the source

Entity
Cellectar Biosciences, Inc. / CIK 0001279704
Captured
2026-09-20T07:48:31.991Z
SEC response SHA-256
44da00fed89c835867d9290b98319109f07ad849957763fd081353f99891a212

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001279704.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))